Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

TOKUSHIMA, Japan — Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status. A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderso

By: financialpost.com

Feb 07 2024
0
0 Views

TOKUSHIMA, Japan -- Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status. Read More

Belo Sun Mining Announces Changes to Executive Leadership

Tree Island Announces Meeting Results for Election of Directors

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

The UK government acted unlawfully in approving a climate plan, a High Court judge has ruled

Glencore-Backed Group Said Near Deal for Shell Singapore Assets

Uranium, Battery, and Precious Metals Virtual Investor Conference: Presentations Now Available for Online Viewing

Mogo to Announce Q1 2024 Financial Results May 9, 2024

Opinion: Time to look at the tax-reform forest, not just the trees

Premier American Uranium Commences Trading on the OTCQB Marketplace

Brookfield Renewable Reports Record First Quarter Results

Plug Signs MOU with Allied Green Ammonia for 3GW of Electrolyzer Supply at World-Class Green Ammonia Production Facility

TransAlta Reports First Quarter 2024 Results

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Related